Menu
Back to Journals » OncoTargets and Therapy » Volume 8
Original Research
A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,659 | Dovepress* | 7,700+ | 1,798 | 9,498 | |
| PubMed Central* | 959 | 459 | 1,418 | ||
| Totals | 8,659 | 2,257 | 10,916 | ||
|
*Since 14 May 2015 +Since July 2016 |
|||||
View citations on PubMed Central and Google Scholar